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Introduction
Rheumatoid arthritis (RA) is a systemic inflammatory disease 
which primarily affects the joints and may also manifest with 
extra-articular symptoms.1 Ocular manifestations can be found in 
25% of patients with RA, and include keratoconjunctivitis sicca, 
peripheral corneal ulceration, keratitis, episcleritis, scleritis, 
choroiditis, and retinal detachments.2,3 Patients with RA not 
treated with effective immunosuppressive therapy may develop 
peripheral ulcerative keratitis, necrotizing scleritis, corneal and 
scleral perforations, which may lead to visual function decrease 
and thereby seriously reduce patients’ quality of life.4
Scleral inflammation caused by RA can manifest as mild 
episcleritis or full-thickness scleritis, which can rarely result in 
scleral melting.5 Scleral thickness has been measured in previous 
studies with ultrasound biomicroscopy as well as with anterior 
segment optical coherence tomography (OCT) in glaucomatous 
patients. In this study we assessed scleral thickness using OCT in 
patients with RA and compared them with healthy volunteers. 
Furthermore, we also utilized enhanced depth imaging (EDI)-
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Abstract
Objectives: To investigate corneal, scleral, choroidal, and foveal thicknesses in female patients with rheumatoid arthritis (RA) and 
compare them with healthy subjects.
Materials and Methods: This prospective study included consecutive female patients diagnosed with RA and healthy subjects. 
Corneal, scleral, choroidal, and retinal (foveal) thicknesses were obtained by using optical coherence tomography and a comparison was 
performed between groups for all outcome measures.
Results: Thirty-six eyes of 36 female patients diagnosed with RA (group 1) and 36 eyes of 36 healthy female volunteers (group 2) were 
included. Mean corneal, scleral, choroidal thicknesses and retinal thickness at the fovea of group 1 were 543.3±33.7 μm, 343.7±42.2 
μm, 214.6±50, and 213.5±18.9 μm, respectively; in group 2, these values were 549.9±29.6 μm, 420.9±42.4 μm, 206.4±41.9 μm, and 
222±15.5 μm, respectively. The comparison between group 1 and 2 with respect to corneal, choroidal, and foveal thicknesses did not 
reveal statistical significant differences (p>0.05). On the contrary, there was a statistically significant difference with respect to scleral 
thickness between the groups, with the RA patients demonstrating a thinner scleral layer (p<0.001).
Conclusion: Female patients with RA seem to demonstrate statistically significant scleral thinning when compared with healthy 
subjects, while there was no difference concerning corneal, choroidal, and foveal thickness.
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OCT, which is a newer technique allowing cross-sectional 
imaging of the retina and choroid. EDI-OCT and anterior 
segment OCT have been used to evaluate retinal and choroidal 
thickness in many ophthalmic diseases; however, there is a lack 
of studies investigating patients with RA.6,7 The current study 
prospectively investigated corneal, scleral, choroidal, and foveal 
thicknesses in female patients with RA and compared the 
outcomes with healthy female subjects.
Materials and Methods 
Patient Population
This prospective study included female patients that were 
diagnosed with RA in accordance with the 2010 RA classification 
of the American Rheumatism Association in the Rheumatology 
Department of Başkent University in Ankara, Turkey between 
June and December 2014. Two groups of subjects were assessed 
in this study; group 1 included eyes of female patients diagnosed 
with RA and group 2 consisted of eyes of healthy female subjects.
The study was approved by the Başkent University 
Institutional Review Board and Ethics Committee (KA 14/26). 
The research adhered to the tenets of the Declaration of Helsinki, 
and detailed written informed consent was obtained before each 
individual’s participation in the study. 
Inclusion and Exclusion Criteria
Female patients over the age of 45 years with positive 
rheumatoid factor and were diagnosed with RA in accordance 
with the 2010 RA classification of the American Rheumatism 
Association were included in the study. In order to avoid refractive 
error magnitude influencing the main outcome measures (corneal, 
choroidal, and scleral thickness), we included patients with 
spherical refractive error between +2 and -2 diopters. Exclusion 
criteria included any corneal or lenticular opacity other than 
mild cataract, history of trauma or surgery that involved the 
conjunctiva or sclera, and history of any other connective tissue 
disease. Patients with active or resolved scleritis, episcleritis, 
keratitis, or uveitis or any history of these were excluded.
Patient Assessment
The participants underwent a complete ophthalmological 
examination which included slit-lamp clinical evaluation of the 
central cornea, perilimbal sclera, central retina, and choroid. 
Corneal and scleral thickness was measured using the Cirrus 
HD-OCT (Carl Zeiss Meditec, Dublin, CA, USA); choroidal and 
foveal thicknesses were measured using the Heidelberg Spectralis 
OCT (Heidelberg Engineering, Heidelberg, Germany). Corneal 
thickness measurements were obtained with the eyes in primary 
gaze position, while scleral thickness measurements were 
obtained using a 45° temporal gaze to measure the sclera 2 mm 
nasal to the corneal limbus (Figures 1 and 2).
Choroidal thickness was measured perpendicularly from 
the outer edge of the retinal pigment epithelium (RPE) to the 
choroid/scleral boundary at the fovea and at 6 more points located 
at 1000 μm nasal to the fovea, 2000 μm nasal to the fovea, 3000 
μm nasal to the fovea, 1000 μm temporal to the fovea, 2000 
μm temporal to the fovea, and 3000 μm temporal to the fovea. 
Retinal thickness was also measured manually from the internal 
limiting membrane to the RPE at the fovea (Figure 3) using 
the caliper provided by OCT software. All measurements were 
taken by two independent blind researchers (O.G. and S.G.G.) 
and were averaged for statistical analysis. Participants were asked 
not to consume drinks containing caffeine and/or eat chocolate 
three hours prior to OCT assessment to avoid possible effects on 
choroidal thickness.
Statistical Analysis
Statistical analysis was performed using SPSS version 20.0 
(Statistical Package for the Social Sciences) software. For each 
variable, normality was checked by Kolmogorov-Smirnov and 
Shapiro-Wilk tests. Mann-Whitney U test was used to evaluate 
Figure 1. Corneal thickness measurements were obtained during straight gaze 
position with optical coherence tomography 
Figure 2. Scleral thickness measurements were obtained during 45 degree 
temporal gaze position with optical coherence tomography
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statistical differences in corneal, scleral, retinal, and choroidal 
thicknesses between groups 1 and 2. Correlation analysis 
between disease duration and measurements of scleral and 
corneal thicknesses were performed by using Spearman’s Rho 
test. Values of p<0.05 were considered statistically significant.
Results
This prospective study included a total of 72 eyes of 72 
female patients. Group 1 comprised 36 eyes of 36 female RA 
patients aged 56.12±9 years (range, 45-69 years); group two 
comprised 36 eyes of 36 healthy females aged 58.13±8 (range, 
45-68 years). Therefore, a total of 86 measurements were done; 
however, 14 measurements were excluded due to poor image 
quality. All the RA patients were under immunosuppressive 
therapy and were followed regularly by their rheumatologists. 
Disease duration after initial diagnosis in the study group (group 
1) was 8.6±1.2 years (median 5.5, range 2-40 years). The groups 
showed no significant difference in age (p>0.05).
Mean corneal thickness was 543.3±33.7 μm (range, 444-612 
μm) in group 1, and 549.9±29.6 μm (range, 496-596 μm) in 
group 2; there was no statistical difference between the groups 
(p>0.05). Mean scleral thickness was 343±42.2 μm (range, 268-
596 μm) in group 1 and 420.9±42.4 μm (range, 354-544 μm) 
in group 2. The difference between the groups was statistically 
significant (p<0.01). Mean retinal thickness as measured from 
the fovea to RPE was 213±18.9 μm (range, 153-249 μm) in 
group 1 and 222±15.5 μm (range, 180-256 μm) in group 2; 
the difference was not statistically significant (p>0.05) (Table 
1). Mean choroidal thickness was averaged from seven points 
at 1000 μm intervals from temporal to nasal choroid across 
the fovea. The differences between the two groups were not 
statistically significant (p>0.05) (Table 2). No correlation was 
Gökmen et al, Ocular Thicknesses in Rheumatoid Arthritis
Figure 3. Measurement of choroidal thickness with enhanced depth imaging-
optical coherence tomography from the outer edge of the retinal pigment 
epithelium (RPE) to the choroid/scleral boundary at the fovea and at 6 more 
points located at 1 mm nasal to the fovea, 2 mm nasal to the fovea, 3 mm nasal to 
the fovea, 1 mm temporal to the fovea, 2 mm temporal to the fovea, and 3 mm 
temporal to the fovea. Retinal thickness was measured from the internal limiting 
membrane to the RPE at the fovea
Table 1. The mean and median corneal, scleral and foveal thicknesses of patients and controls
Group 1 (in µm) Group 2 (in µm)
p
Mean ± SD
Median (minimum- 
maximum)
Mean ± SD
Median (minimum-
maximum)
Cornea 543.3±33.7 542 (444-612) 549.9±29.6 550 (496-596) 0.388
Sclera 343.7±42.2 332 (268-596) 420.9±42.4 420 (345-544) 0.001
Fovea 213.5±18.9 218 (153-249) 222±15.5 222 (180-256) 0.68
SD: Standard deviation
Table 2. The mean and median choroidal thicknesses of patients and controls at 7 points
Mean ± SD (in µm) Median (minimum-maximum) (in µm)
p
Group 1 Group 2 Group 1 Group 2
Nasal 3 mm 153.9±48.6 154±43.8 155 (56-284) 158 (70-248) 0.954
Nasal 2 mm 195.0±54.6 188.4±52.3 197 (86-314) 196 (90-337) 0.608
Nasal 1 mm 227.6±64.0 221±50.6 226 (95-438) 226 (124-345) 0.822
Foveal 261.5±61.8 254.4±56.7 258 (107-445) 238 (145-402) 0.270
Temporal 1 mm 239.5±58.3 226.9±58.4 233 (102-428) 217 (129-469) 0.130
Temporal 2 mm 220.7±46.3 207±53.2 211 (116-365) 197 (109-331) 0.139
Temporal 3 mm 200.8±56.5 192±50.2 192 (104-457) 190 (104-338) 0.652
Average 214.6±50.4 206.4±41.9 206 (95-362) 106 (112-295) 0.517
SD: Standard deviation
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found between disease duration and corneal thickness or scleral 
thickness (p=0.316).
Discussion
RA is usually associated with extra-articular findings. 
Turesson et al.8 evaluated 609 RA patients from 1955 to 1994 
and showed that 247 patients (41%) had at least one extra-
articular finding. The most frequent ocular manifestation of RA is 
keratoconjunctivitis sicca.8 Other reported ocular complications 
of RA are episcleritis, scleritis, retinal vasculitis, peripheral 
ulcerative keratitis, and interstitial keratitis.9 Cytokines such 
as interleukin 1 (IL-1), IL-6, and tumor necrosis factor alpha 
(TNF-α) are believed to play a major role in the development 
of extra-articular findings in RA. The efficacy of anti-TNF-α 
agents like infliximab further support this hypothesis.10 An 
imbalance of these pro- and anti-inflammatory cytokines creates 
a microenvironment that supports the breakdown of collagen in 
RA. This can manifest as keratitis starting from the perilimbal 
cornea and spreading toward the central cornea, causing corneal 
melting and perforations.11,12
The mechanisms of action of RA suggest that manifestations 
in different ocular tissues and macrostructural tissue changes 
(pachymetric alterations, etc.) could occur in patients with 
RA. In our study we assessed corneal, scleral, choroidal, and 
foveal thickness in order to identify possible implications 
of RA on macrostructural tissue alterations with respect to 
thickness. According to the literature, most of the studies 
have measured central corneal thickness in RA patients using 
confocal microscopy, pachymetry, Scheimpflug imaging systems, 
and ocular response analyzers. However, none of them utilized 
OCT.13,14,15,16 Therefore, we aimed to measure central corneal 
thickness using anterior segment-OCT in RA patients and we 
did not detect a statistical significant difference between patients 
with RA and healthy subjects with respect to central corneal 
thickness. This finding may suggest that patients actively 
managed with immunomodulatory agents (like the RA patients 
in this study) do not do demonstrate corneal thinning.
The choroidal layer is the most vascularized layer in the eye, 
so it can play a role in many ophthalmologic diseases. Newly 
developed OCT applications (EDI-OCT) allowing cross-sectional 
imaging of the choroid, and several studies have demonstrated 
that choroidal thickness changes in ocular diseases such as 
age-related macular degeneration, high myopia, chorioretinal 
atrophies, Vogt-Koyanagi-Harada disease, Behçet’s disease, 
sarcoidosis uveitis, and polypoidal choroidal vasculopathy.6,17,18 
Despite improvements in software analysis, studies have also 
shown that manual retinal and choroidal thickness measurements 
are still superior to automated measurements.19,20 In the current 
study we measured choroidal and retinal thicknesses of RA 
patients manually with the caliper provided by the Spectralis 
OCT software. According to our results, there was no statistically 
significant difference with respect to choroidal and retinal 
thickness when compared to healthy subjects. As our patients 
were all under active immunomodulatory treatment, this may 
have prevented choroidal tissue alterations; possible changes in 
choroidal thickness may be evident in patients with uncontrolled 
RA. Nevertheless, choroidal involvement is rare in RA; it is 
usually a finding after inflammation due to posterior scleritis, 
which in turn is also rare. Therefore, immunosuppressive 
treatment may not be the reason for this, as retinal changes are 
very rare in RA. Given that the current study has a small sample 
size, the absence of structural changes of the retina may not be 
indicative. Further studies including patients with uncontrolled 
RA are needed to investigate the effect of RA on the choroid. 
Scleritis in RA has a reported prevalence of 0.63-
0.67%. Furthermore, scleral thinning and perforation due to 
inflammatory vasculitis or scleromalacia perforans rarely occurs 
in patients with RA.21 While scleritis may lead to scleral 
thinning and melting, the pathogenesis of scleritis in RA is 
still unknown.22 In our study, although none of our RA patients 
had active scleritis, inflammatory vasculitis, or scleromalacia 
perforans, they demonstrated a significant decrease in scleral 
thickness when compared to the healthy subjects (p<0.001). 
The etiology of this thinning is unclear but may be related 
to subclinical immune complex deposition and destruction of 
scleral tissues despite appropriate immunosuppressive therapy. In 
addition, we evaluated scleral thickness as correlated to disease 
duration and found no correlation between them. However, the 
disease progression rate can be quite variable, and the small size 
of our study may have affected this correlation.
Study Limitations
A limitation of the current study is the small number of 
eyes included. Furthermore, there is a selection bias with respect 
to the gender included in the study; we only included female 
patients as the number of male patients was very small. Our 
inability to include more male patients can be attributed to the 
3-fold higher incidence of RA in the female population when 
compared to males.23 Another limitation of the current study is 
the lack of a positive control (a group of subjects with diseases 
other than RA that manifest with scleritis). This would add to 
the current study and provide further scientific validation of the 
outcomes described herein. We only included a normal (healthy) 
group of female patients that served as controls, as we did not 
locate a sufficient number of subjects with diseases other than 
RA that manifest with scleritis. Finally, the images acquired by 
the Cirrus HD-OCT are not of high resolution and quality due 
to the capabilities of the current imaging platform; nevertheless, 
pachymetric measurements should not be influenced by this 
limitation.24,25
Conclusion
This study shows that scleral thinning occurs in female 
patients with RA under active immunomodulatory treatment 
and no active scleritis, inflammatory vasculitis, or scleromalacia. 
This could be caused by a chronic inflammatory process, 
subclinical immune complex deposition, or direct destruction of 
scleral tissues by autoimmune reaction. Patients with RA could 
be followed for possible scleral thinning and perforations as there 
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seems to be a tendency towards thinning despite appropriate 
immunomodulatory control. Corneal, retinal, and choroidal 
thicknesses, however, should be normal in properly treated 
patients.
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